Olivier Wurtz

Olivier Wurtz

Auto-generated profile, based on publicly available information

Olivier Wurtz

A Normandie Univ, UNIROUEN, INSERM, DC2N , Rouen , France

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2009 in Pharmacological Reviews
Verified
Journal Article
Closed access
PDF file
David VaudryDavid Vaudry
David Vaudry
AFAnthony Falluel-Morel
Anthony Falluel-Morel
SBSteve Bourgault
Steve Bourgault
MBMagali Basille
Magali Basille
DBDelphine Burel
Delphine Burel
HVHubert Vaudry
Hubert Vaudry
Pituitary adenylate cyclase-activating polypeptide (PACAP) is a 38-amino acid C-terminally α-amidated peptide that was first isolated 20 years ago from an ovine hypothalamic extract on the basis of its ability to stimulate cAMP formation in anterior pituitary cells (Miyata et al., 1989. PACAP belongs to the vasoactive intestinal polypeptide (VIP)-secretin-growth hormone-releasing hormone-glucagon superfamily. The sequence of PACAP has been remarkably well conserved during evolution from protochordates to mammals, suggesting that PACAP is involved in the regulation of important biological functions. PACAP is widely distributed in the brain and peripheral organs, notably in the endocrine pancreas, gonads, respiratory and urogenital tracts. Characterization of the PACAP precursor has revealed the existence of a PACAP-related peptide, the activity of which remains unknown. Two types of PACAP binding sites have been characterized: type I binding sites exhibit a high affinity for PACAP and a much lower affinity for VIP, whereas type II binding sites have similar affinity for PACAP and VIP. Molecular cloning of PACAP receptors has shown the existence of three distinct receptor subtypes: the PACAP-specific PAC1-R, which is coupled to several transduction systems, and the PACAP/VIP-indifferent VPAC1-R and VPAC2-R, which are primarily coupled to adenylyl cyclase. PAC1-Rs are particularly abundant in the brain, the pituitary and the adrenal gland, whereas VPAC receptors are expressed mainly in lung, liver, and testis. The development of transgenic animal models and specific PACAP receptor ligands has strongly contributed to deciphering the various actions of PACAP. Consistent with the wide distribution of PACAP and its receptors, the peptide has now been shown to exert a large array of pharmacological effects and biological functions. The present report reviews the current knowledge concerning the pleiotropic actions of PACAP and discusses its possible use for future therapeutic applications.

6 July 2006 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
PLPierre-François Lenne
Pierre-François Lenne
LWLaure Wawrezinieck
Laure Wawrezinieck
FCFabien Conchonaud
Fabien Conchonaud
OWOlivier Wurtz
Olivier Wurtz
ABAnnie Boned
Annie Boned
DMDidier Marguet
Didier Marguet
It is by now widely recognized that cell membranes show complex patterns of lateral organization. Two mechanisms involving either a lipid‐dependent (microdomain model) or cytoskeleton‐based (meshwork model) process are thought to be responsible for these plasma membrane organizations. In the present study, fluorescence correlation spectroscopy measurements on various spatial scales were performed in order to directly identify and characterize these two processes in live cells with a high temporal resolution, without any loss of spatial information. Putative raft markers were found to be dynamically compartmented within tens of milliseconds into small microdomains (∅<120 nm) that are sensitive to the cholesterol and sphingomyelin levels, whereas actin‐based cytoskeleton barriers are responsible for the confinement of the transferrin receptor protein. A free‐like diffusion was observed when both the lipid‐dependent and cytoskeleton‐based organizations were disrupted, which suggests that these are two main compartmentalizing forces at work in the plasma membrane.

1 February 2015 in Stroke
Verified
Journal Article
Closed access
PDF file
CBCoralie Brifault
Coralie Brifault
MGMarjorie Gras
Marjorie Gras
DLDonovan Liot
Donovan Liot
VMVictor May
Victor May
David VaudryDavid Vaudry
David Vaudry
OWOlivier Wurtz
Olivier Wurtz
Background and Purpose—: Until now, except thrombolysis, the therapeutical strategies targeting the acute phase of cerebral ischemia have been proven ineffective, and no approach is available to attenuate the delayed cell death mechanisms and the resulting functional deficits in the late phase. Then, we investigated whether a targeted and delayed delivery of pituitary adenylate cyclase–activating polypeptide (PACAP), a peptide known to exert neuroprotective activities, may dampen delayed pathophysiological processes improving functional recovery. Methods—: Three days after permanent focal ischemia, PACAP-producing stem cells were transplanted intracerebro ventricularly in nonimmunosuppressed mice. At 7 and 14 days post ischemia, the effects of this stem cell–based targeted delivery of PACAP on functional recovery, volume lesions, and inflammatory processes were analyzed. Results—: The delivery of PACAP in the vicinity of the infarct zone 3 days post stroke promotes fast, stable, and efficient functional recovery. This was correlated with a modulation of the postischemic inflammatory response. Transcriptomic and Ingenuity Pathway Analysis–based bioinformatic analyses identified several gene networks, functions, and key transcriptional factors, such as nuclear factor-κB, C/EBP-β, and Notch/RBP-J as PACAP’s potential targets. Such PACAP-dependent immunomodulation was further confirmed by morphometric and phenotypic analyses of microglial cells showing increased number of Arginase-1 + cells in mice treated with PACAP-expressing cells specifically, demonstrating the redirection of the microglial response toward a neuroprotective M2 phenotype. Conclusions—: Our results demonstrated that immunomodulatory strategies capable of redirecting the microglial response toward a neuroprotective M2 phenotype in the late phase of brain ischemia could represent attractive options for stroke treatment in a new and unexploited therapeutical window.

15 February 2002 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
MBMarc BajénOff
Marc BajénOff
OWOlivier Wurtz
Olivier Wurtz
SGSylvie Guerder
Sylvie Guerder
The mechanisms that regulate CD4+ T cells responses in vivo are still poorly understood. We show here that initial Ag stimulation induces in CD4+ T cells a program of proliferation that can develop, for at least seven cycles of division, in the absence of subsequent Ag or cytokine requirement. Thereafter, proliferation stops but can be reinitiated by novel Ag stimulation. This initial Ag stimulation does not however suffice to induce the differentiation of naive CD4+ T cells into effector Th1 cells which requires multiple contacts with Ag-loaded APC. Thus, recurrent exposure to both Ag and polarizing cytokines appears to be essential for the differentiation of IFN-γ-producing cells. Ag and cytokine availability therefore greatly limits the differentiation, but not the initial proliferation, of CD4+ T cells into IFN-γ-producing cells.

1 March 2004 in International Immunology
Verified
Journal Article
Open access
PDF file
OWOlivier Wurtz
Olivier Wurtz
MBMarc Bajénoff
Marc Bajénoff
SGSylvie Guerder
Sylvie Guerder
The mechanisms by which Th1 and Th2 cells inter‐regulate in vivo are still poorly understood. In this study we examined the plasticity of Th1 cell differentiation and how Th2 cells may down‐regulate these responses. We show here that IL‐4 affects Th1 cell responses by two developmentally regulated mechanisms. During the commitment phase of naive CD4+ T cells, IL‐4 inhibits Th1 cell differentiation and induces a reversion of developing Th1 cells to the Th2 lineage. In contrast, for effector Th1 cells IL‐4 does not affect the developmental process, but only the transcription of the IFN‐γ gene. We further show that the difference in IL‐4 responsiveness correlates with a loss, in effector Th1 cells, of IL‐4‐dependent up‐regulation of GATA‐3 expression despite normal activation of STAT6. Transient inhibition of IFN‐γ production by differentiated effector cells may explain why Th1 and Th2 responses can co‐exist in vivo although Th2 effector cells dominate functionally, as observed in some infectious or autoimmune mice models.

1 September 2007 in Peptides
Verified
Journal Article
Closed access
BBBéatrice Botia
Béatrice Botia
MBMagali Basille
Magali Basille
AAAurélie Allais
Aurélie Allais
EREmilie Raoult
Emilie Raoult
AFAnthony Falluel-Morel
Anthony Falluel-Morel
David VaudryDavid Vaudry
David Vaudry